hotspot -WSS

hotspot

author：explore 2025-09-28 03:36:37 - browse：39723

When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

“If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Inside the culture of fear in the White House science office of Eric Lander

hotspot

leisure time

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

FDA's Pazdur wants cancer trials to range beyond China alone

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

At ASCO, AstraZeneca reports strong data for breast cancer drug

Ionis drug prevents swelling attacks due to hereditary angioedema

Statins reduce cardiovascular risk in people living with HIV

Wikipedia

hotspot

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to protect coverage of PrEP

Alkermes shareholders re

NIH documents show early flaws of $1.6 billion long Covid program

What does generative AI mean for health care? We asked experts

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Anesthesiologist group: stop taking Ozempic before surgery

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Moonlake's readout produced a cash windfall. Risks remain

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

focus

NIH documents show early flaws of $1.6 billion long Covid program

Change Healthcare can notify patients about the breach, HHS says

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

At ASCO, AstraZeneca reports strong data for breast cancer drug

Shifting the focus from loneliness to social health

Kaiser's Risant Health gobbled up Geisinger. Who is next?

hotspot

hotspot

leisure time

entertainment